

REMARKS

The specification has been amended to reflect the national stage status.

Claim 5 has been amended to remove the multiple dependency.

Claim 15 has been amended to require the presence of a pharmaceutically acceptable carrier in conformance with U.S. practice. Support is found in the specification at page 55, line 12.

Claims 22 and 23 have been rewritten in conformance with U.S. practice so as to be directed to a method for production. In addition, the claim has been amended to require the presence of a pharmaceutically acceptable carrier, which is supported on page 55, line 12 of the specification.

Lastly, claim 24 has been amended to remove the improper multiple dependency.

Favorable action on the merits is solicited.

Respectfully submitted,

Keiji KAMIYAMA et al.

By

Warren M. Cheek, Jr.

Registration No. 33,367
Attorney for Applicants

WMC/dlk
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
December 13, 2004